Recursion Pharmaceuticals Reports Q1 2026 Earnings and Provides Business Update
Recursion Pharmaceuticals (RXRX) reported a 30% year-over-year reduction in cash operating expenses and ended the quarter with $665 million in cash and equivalents, providing operating runway through early 2028. The company also highlighted progress in multiple clinical programs and received a milestone payment from Sanofi.
Topics: cash position clinical trials financial performance milestone payments operating expenses